VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Up 24.4% in December

VolitionRX Limited (NYSEAMERICAN:VNRX) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totaling 676,713 shares, an increase of 24.4% from the December 15th total of 543,884 shares. Currently, 0.6% of the company’s shares are sold short. Based on an average daily trading volume, of 2,688,706 shares, the short-interest ratio is currently 0.3 days. Based on an average daily trading volume, of 2,688,706 shares, the short-interest ratio is currently 0.3 days. Currently, 0.6% of the company’s shares are sold short.

VolitionRX Stock Performance

Shares of NYSEAMERICAN VNRX traded up $0.00 during midday trading on Friday, reaching $0.29. The stock had a trading volume of 723,487 shares, compared to its average volume of 1,959,771. The firm has a market cap of $36.00 million, a price-to-earnings ratio of -1.27 and a beta of 1.23. VolitionRX has a twelve month low of $0.22 and a twelve month high of $0.94. The company’s 50 day moving average price is $0.30 and its 200 day moving average price is $0.50.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.